Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth

— Series C supported by premier syndicate including co-leads Ascenta Capital and Janus Henderson Investors with significant participation from Deep Track plus existing investors — — Funding enables larger Phase 2 clinical proof-of-concept trial evaluating IL-13 and KLK5/7 dual-targeting antibody in atopic dermatitis — — Evan Rachlin, M.D., Co-Founder and Managing Partner of Ascenta Capital, […] The post Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth appeared first on Triveni Bio .